This page shows the SEC filing summaries for SpyGlass Pharma, Inc..
SpyGlass Pharma, Inc.
CIK: 1778922 · 2 filings tracked
Filing History
1
10-K
Annual Report
March 26, 2026
- Phase 3 clinical trials for the BIM-IOL System are underway with 600 patients.
- Early trial data shows a 37% reduction in eye pressure and 95% of patients stopping daily drops.
- Utilizes a streamlined FDA regulatory pathway by using a previously approved glaucoma medication.
2
S-1
IPO Filing
January 16, 2026
- Innovative BIM-IOL System provides 3-year sustained drug delivery for glaucoma, eliminating the need for daily eye drops.
- Leverages approximately 3.5 million annual U.S. cataract surgeries, integrating treatment into a common procedure.
- Early human trials show promising results: 37% average eye pressure reduction and 95% of patients off daily eye drops after three years.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.